ANALISIS YURIDIS PENGELOLAAN OBAT HEPATITIS B BERSUBSIDI DALAM SISTEM FARMASI RUMAH SAKIT DI INDONESIA

Authors

  • Maria Aryanthi Ledjap Universitas Bhakti Asih Tangerang, Indonesia
  • Ramlin Ahmad Universitas Bhakti Asih Tangerang, Indonesia
  • Muhammad Syafi’I Universitas Bhakti Asih Tangerang, Indonesia

DOI:

https://doi.org/10.51826/perahu.v14i1.1853

Keywords:

Health Law, Subsidized Medicines, Hepatitis B, Hospital Pharmacy System, Legal Accountability

Abstract

The management of subsidized Hepatitis B medicines in hospital pharmacy systems remains vulnerable to administrative irregularities, ethical violations, and legal non-compliance, potentially undermining patients’ rights to equitable and transparent healthcare. This study analyzes the juridical framework governing such management and examines deviations in practice along with resulting legal responsibilities. Using a normative juridical method with statutory, conceptual, and case approaches, this research relies on primary, secondary, and tertiary legal materials analyzed qualitatively. The findings indicate that despite comprehensive pharmaceutical regulations in Indonesia, implementation at the hospital level has not fully reflected principles of transparency, accountability, and justice. Deviations include maladministration, misappropriation in drug distribution, and weak internal supervision. These conditions result in layered legal consequences, including administrative sanctions, ethical liability, and potential criminal responsibility. Strengthening regulatory enforcement, improving pharmaceutical audits, and enhancing legal awareness are necessary to ensure accountable and equitable management of subsidized medicines.

References

Adepoju, V. A., Udah, D. C., Ezenwa, C. A., & Ganiyu, J. (2024). Coverage and restrictions in access to viral hepatitis services. International Journal of Environmental Research and Public Health, 21(10), 1373. https://doi.org/10.3390/ijerph21101373

Badan Pemeriksa Keuangan Republik Indonesia. (2023). Laporan hasil pemeriksaan atas program obat bersubsidi nasional. Jakarta: BPK RI.

Beauchamp, T. L., & Childress, J. F. (2009). Principles of biomedical ethics (7th ed.). Oxford University Press.

Chen, J., Jia, J., Zhuang, H., Zhang, W., & Yang, J. M. (2025). Assessing pricing and affordability of HBV treatment in Asia–Pacific region: A barrier to elimination. Hepatology International, 19(1), 55–67. https://doi.org/10.1007/s12072-024-10744-9

Fahadayna, A. C., & Hair, A. (2024). Mapping the extraordinary measure disease outbreak

(EMDO): An analysis of health regulations in Indonesia 2000–2023. World Medical & Health Policy, 16(2), 112–128. https://doi.org/10.1002/wmh3.593

Hadjon, P. M. (2008). Pengantar hukum administrasi Indonesia. Gadjah Mada University Press. Kelsen, H. (1961). General theory of law and state. Russell & Russell.

Marzuki, P. M. (2017). Penelitian hukum. Kencana.

Nasution, B. J. (2017). Metode penelitian ilmu hukum. Mandar Maju.

Republik Indonesia. (1945). Undang-Undang Dasar Negara Republik Indonesia Tahun 1945. Republik Indonesia. (2009). Undang-Undang Nomor 36 Tahun 2009 tentang Kesehatan.

Lembaran Negara Republik Indonesia Tahun 2009 Nomor 144.

Republik Indonesia. (2009). Undang-Undang Nomor 44 Tahun 2009 tentang Rumah Sakit.

Lembaran Negara Republik Indonesia Tahun 2009 Nomor 153.

Republik Indonesia. (2016). Peraturan Menteri Kesehatan Nomor 72 Tahun 2016 tentang Standar Pelayanan Kefarmasian di Rumah Sakit. Kementerian Kesehatan Republik Indonesia.

Sinuraya, R. K., & Suwantika, A. A. (2025). Enhancing COVID-19 vaccination as a public programme in Indonesia. Global Security: Health, Science and Policy, 10(1), 25–39. https://doi.org/10.1080/23779497.2025.1048992

Soekanto, S., & Mamudji, S. (2019). Penelitian hukum normatif: Suatu tinjauan singkat (Edisi revisi). Raja Grafindo Persada.

Tjandrawinata, R. R. (2025). Innovative models for high-cost medicines: A comparative analysis across the US, Indonesia, and Asia. Asian Journal of Engineering, Social and Health, 5(2), 144–158.

World Health Organization. (2024). Global hepatitis report 2024: Action for access in low- and middle-income countries. WHO Press.

Published

04/03/2026

Citation Check